The ALS Association recently pledged a $2 million contribution aimed at augmenting the work of its ALS ONE-Massachusetts ALS Partnership (MAP), a new coalition of four aligned specialty health care organizations.
This quartet of institutions — all located in Massachusetts — includes Massachusetts General Hospital (MGH) in Boston; ALS Therapy Development Institute (ALS TDI) of Cambridge; University of Massachusetts Medical School in Worcester; and Compassionate Care ALS (CCALS) of Falmouth.
The facilities are collaborating on projects dedicated to finding treatments or a cure for amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig’s Disease.
Besides the $2 million donation from the ALS Association, the consortium is utilizing another $2 million contributed from ALS Funding a Cure — plus $2 million from ALS ONE itself — for a working total of $6 million.
“The collaboration among these distinguished centers of ALS research will help accelerate the development of meaningful new approaches to treatment,” Dr. Lucie Bruijn, chief scientist at The ALS Association and board member of ALS ONE, said. “We are gratified to be able to help these partnerships bring their expertise to bear on this important goal, and are excited by the potential they represent.”
ALS is a progressive neurodegenerative disease impacting brain and spinal cord nerve cells. The ALS Association is a nonprofit organization dedicated to fighting Lou Gehrig’s Disease via research, a network of national chapters, government partnerships and multidisciplinary care.
